This explains the result that enhanced CENPL predicts poor prognosis and also provides a basis for finding new immunotherapy methods for HCC patients with poor response to PD-1 antibodies and other immunosuppressive agents. Here, PDCD1 is linked to hepatocellular carcinoma.